Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival

@inproceedings{Overmoyer2015AbstractPE,
  title={Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival},
  author={Beth Overmoyer and Pedro Sanz-Altimira and Ann H Partridge and Martine Extermann and Jane Liu and Eric P. Winer and Nan Lin and Michael J. Hassett and Leroy Monroe Parker and Ryan P. Taylor and Michael L. Hancock and Susan Small and Mary Ann Johnston},
  year={2015}
}
Background: Historically, androgens have been utilized for the treatment of breast cancer (BC) as the androgen receptor (AR) is the most highly expressed steroid receptor in BC (75-95% of estrogen receptor positive (ER+) and 50% of ER negative). Reports of the use of androgens in metastatic BC (MBC) indicate that women progressing on tamoxifen have the ability to respond to synthetic androgens with overall response rates in the range of 20-60%; however, these steroidal androgens also exhibit… CONTINUE READING